Do we have a bladder-intact cure for muscle invasive bladder cancer?

Alexandre R. Zlotta, MD, PhD, Mount Sinai Hospital and University of Toronto, Toronto, Canada, discusses how far away we are from a bladder-intact cure for muscle-invasive bladder cancer. Currently, bladder-sparing trimodality therapy is often used only for patients who are not eligible for surgery, making it difficult to compare the outcomes of the two treatment options. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.